Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Concord Biotech Limited (NSE: CONCORDBIO), ISIN INE338H01029 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
CONCORDBIO last traded at ₹597.30 (-5.58%), with a 52-week range of ₹493.50 to ₹807.50 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 44.09%, FIIs 7.28%, DIIs 10.95%, mutual funds 5.84%.
EquiSense Score (ECS): 60/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.